Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open-Label, Parallel Group, International, Multicenter, Phase III Study of Oral ZD1839 (IRESSA) [gefitinib] Versus Intravenous Docetaxel (TAXOTERE) in Patients With Locally Advanced or Metastatic Recurrent Non-Small Cell Lung Cancer Who Have Previously Received Platinum-Based Chemotherapy

Next Previous
X
Search
Trial Profile

A Randomized, Open-Label, Parallel Group, International, Multicenter, Phase III Study of Oral ZD1839 (IRESSA) [gefitinib] Versus Intravenous Docetaxel (TAXOTERE) in Patients With Locally Advanced or Metastatic Recurrent Non-Small Cell Lung Cancer Who Have Previously Received Platinum-Based Chemotherapy

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jun 2011

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gefitinib (Primary) ; Docetaxel
  • Indications Non-small cell lung cancer
  • Focus Biomarker; Registrational; Therapeutic Use
  • Acronyms INTEREST
  • Sponsors AstraZeneca

    • Most Recent Events

    • 12 May 2011 Actual end date (October 2007) added as reported by ClinicalTrials.gov.
    • 12 May 2011 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
    • 27 Jan 2011 Actual end date changed from 5 Sep 2007 to 1 Jun 2006 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top